Why this evidence?
It is linked to a specific model version, scientific task, dataset, split, metric and source. That makes the claim inspectable rather than a detached marketing score.
Boltz-1 / Boltz-2: Biomolecular complex prediction
Open evaluation reports structure prediction and later affinity capabilities.
Model versionBoltz-2
TaskBiomolecular complex prediction
DatasetPoseBusters and affinity benchmarks
SplitPoseBusters and affinity evaluation sets
MetricStructure and affinity
Replicationpartial
Reported byModel developers and open community evaluations
Review statuscurated
Evidence confidence · limited
Confidence is multidimensional, not a universal model score.
Evidence completenessstrongModel version, task, dataset, split, metric, source and provenance fields.
Independent validationmoderatepartial
Source qualitylimitedPreprint / open evaluation
Reproducibility evidencemoderateReflects documented replication status, not a universal reproducibility score.
Version specificitystrongBoltz-2
Context applicabilitystrongDepends on task, split and explicit caveats; users must still validate their own context.
Contradiction reviewclearNo direct contradiction signal is currently queued.
BioAtlas reports evidence dimensions separately so a strong source cannot hide weak applicability, incomplete replication or unresolved contradiction.
Why?
Why should this evidence influence a decision?
Why not a universal score?
Performance can change with dataset, split, preprocessing, metric and context of use. BioAtlas therefore keeps confidence dimensions separate.
What could change the conclusion?
Independent replication, a better matched prospective dataset, a version change, a contradictory result or a more relevant validation protocol can reopen this evidence record.
Evidence boundary
What this claim does not prove.
- Boltz-1 structure claims and Boltz-2 affinity claims should be separated by version.
- Affinity performance depends strongly on target family and split design.
BioAtlas groups benchmark claims only when task, dataset, split, metric and protocol context align. This record is not a universal model score.
Model context
Boltz-1 was the first fully open, commercially-usable model to match AlphaFold 3 on biomolecular complex prediction. Boltz-2 (2025) added fast, accurate binding-affinity prediction — approaching physics-based free-energy methods at a fraction of the cost — a key missing piece for virtual screening.
Full evidence passport →Known model limitations
- Performance depends on the evaluation dataset and operating conditions.
- Task-specific benchmark results should not be compared across unlike domains.
- Outputs require task-specific scientific and experimental validation.